<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03538743</url>
  </required_header>
  <id_info>
    <org_study_id>C3421002</org_study_id>
    <nct_id>NCT03538743</nct_id>
  </id_info>
  <brief_title>4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants
      will receive an investigational product or placebo for 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Actual">June 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With All-causality and Treatment-related Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From baseline to up to 35 days after last dose for a total of approximately 63 days</time_frame>
    <description>Treatment-related adverse event (AE) was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality</measure>
    <time_frame>From baseline to up to 14 days after last dose for a total of approximately 42 days</time_frame>
    <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs</measure>
    <time_frame>From baseline to up to 14 days after last dose for a total of approximately 42 days</time_frame>
    <description>Vital signs categorical summarization criteria: 1) supine systolic blood pressure (SBP) &lt;90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) &lt;50 mmHg; 3) supine pulse rate &lt;40 or &gt;120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (&gt;=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP &gt;= 20 mmHg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Interval</measure>
    <time_frame>From baseline to up to 14 days after last dose for a total of approximately 42 days</time_frame>
    <description>ECG categorical summarization criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (&gt;=) 300 millisecond (msec), b) &gt;=25% increase when baseline is &gt; 200 msec or &gt;=50% increase when baseline is less than or equal to (&lt;=) 200 msec.
2. QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) &gt;=140 msec, b) &gt;=50% increase from baseline.
3. QTcF interval (QT corrected using the Fridericia formula): a) &gt;450 msec and &lt;=480 msec, b) &gt;480 msec and &lt;=500 msec, c) &gt;500 msec, d) &gt;30 msec and &lt;=60 msec increase from baseline, e) &gt;60 msec increase from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC24 and AUCtau of PF-06882961 on Day 1, Day 14 or 21 and Day 28</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 1, 14 or 21, and 28</time_frame>
    <description>Area under the concentration-time profile from time zero to time 24 hours (AUC24) was calculated as AUCtau1 +AUCtau2, where AUCtau was area under the plasma concentration-time profile from time zero to time tau (tau1 = 0 to 10 hours and tau2=10 to 24 hours). AUCtau was determined using linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of PF-06882961 on Day 1, Day 14 or 21 and Day 28</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1, 14 or 21, and 28</time_frame>
    <description>For BID dosing, parameters were calculated for both dosing intervals (0-10 hr = interval 1 and 10-24 hr = interval 2) and were displayed as Cmax1, Cmax2.
Cmax1: maximum plasma concentration during the dosing interval τ1 =0 to 10 hours.
Cmax2: maximum plasma concentration during the dosing interval τ2=10 to 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for Cmax (Tmax) of PF-06882961 on Day 1, Day 14 or 21 and Day 28</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 1, 14 or 21, and 28</time_frame>
    <description>Time for Cmax, Cmax1 and Cmax2 (Tmax, Tmax1 and Tmax2) of PF-06293620 was observed directly from data as time of first occurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t½) of PF-06882961 on Day 28</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 28</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Unchanged Drug Recovered in Urine Over 24 Hours (Ae24) of PF-06882961 on Day 28</measure>
    <time_frame>0 to 24 hours post-dose on Day 28</time_frame>
    <description>Ae was the cumulative amount of drug recovered unchanged in urine during the dosing interval, where the dosing interval was 24 hours. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram [g]/1.020), where 1.020 g/mL was the approximate specific gravity of urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae24 (%) of PF-06882961 on Day 28</measure>
    <time_frame>0 to 24 hours post-dose on Day 28</time_frame>
    <description>Percent of dose recovered in urine as unchanged drug. Ae24% = 100* Ae24/Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr) of PF-06882961 on Day 28</measure>
    <time_frame>0 to 24 hours post-dose on Day 28</time_frame>
    <description>CLr was calculated as Ae divided by AUCtau, where dosing interval is 24 hours.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 dose TBD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 dose TBD Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 dose TBD Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06882961 dose TBD Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, 0 mg, twice daily, 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, 15 mg twice daily, 28 days</description>
    <arm_group_label>PF-06882961 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, 50 mg twice daily, 28 days</description>
    <arm_group_label>PF-06882961 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, 150 mg twice daily, 28 days</description>
    <arm_group_label>PF-06882961 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, 300 mg twice daily, 28 days</description>
    <arm_group_label>PF-06882961 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, dose TBD, twice daily, Cohort 5, 28 days</description>
    <arm_group_label>PF-06882961 dose TBD Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, dose TBD, twice daily, Cohort 6, 28 days</description>
    <arm_group_label>PF-06882961 dose TBD Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, dose TBD, twice daily, Cohort 7, 28 days</description>
    <arm_group_label>PF-06882961 dose TBD Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Tablet, dose TBD, twice daily, Cohort 8, 28 days</description>
    <arm_group_label>PF-06882961 dose TBD Cohort 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes treated with a stable dose of metformin at least 500 mg

          -  HbA1c value between 7.0 and 10.5%

        Exclusion Criteria:

        - Type 1 diabetes or secondary forms of diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qps-Mra, Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qps-Mra,Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3421002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <results_first_submitted>May 8, 2020</results_first_submitted>
  <results_first_submitted_qc>June 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2020</results_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03538743/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03538743/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo matched to PF-06882961 was administered orally once daily (QD) or twice daily (BID) (dependent upon corresponding study treatment regimen) for a total of 28 days.</description>
        </group>
        <group group_id="P2">
          <title>PF-06882961 10mg BID</title>
          <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
        </group>
        <group group_id="P3">
          <title>PF-06882961 15mg BID</title>
          <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
        </group>
        <group group_id="P4">
          <title>PF-06882961 50mg BID</title>
          <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
        </group>
        <group group_id="P5">
          <title>PF-06882961 70mg BID</title>
          <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="P6">
          <title>PF-06882961 120mg BID</title>
          <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="P7">
          <title>PF-06882961 120mg BID Slow Titration (ST)</title>
          <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="P8">
          <title>PF-06882961 120mg QD</title>
          <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
        </group>
        <group group_id="P9">
          <title>PF-06882961 200mg QD Controlled Release (CR)</title>
          <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Treatment-Related Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo matched to PF-06882961 was administered orally QD or BID(dependent upon corresponding study treatment regimen) for a total of 28 days.</description>
        </group>
        <group group_id="B2">
          <title>PF-06882961 10mg BID</title>
          <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
        </group>
        <group group_id="B3">
          <title>PF-06882961 15mg BID</title>
          <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
        </group>
        <group group_id="B4">
          <title>PF-06882961 50mg BID</title>
          <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
        </group>
        <group group_id="B5">
          <title>PF-06882961 70mg BID</title>
          <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="B6">
          <title>PF-06882961 120mg BID</title>
          <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="B7">
          <title>PF-06882961 120mg BID ST</title>
          <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="B8">
          <title>PF-06882961 120mg QD</title>
          <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
        </group>
        <group group_id="B9">
          <title>PF-06882961 200mg QD CR</title>
          <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="9"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="10"/>
            <count group_id="B10" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18-44 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>45-64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age Range</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" lower_limit="41" upper_limit="70"/>
                    <measurement group_id="B2" value="55.0" lower_limit="44" upper_limit="61"/>
                    <measurement group_id="B3" value="55.0" lower_limit="37" upper_limit="68"/>
                    <measurement group_id="B4" value="63.5" lower_limit="48" upper_limit="68"/>
                    <measurement group_id="B5" value="60.0" lower_limit="46" upper_limit="65"/>
                    <measurement group_id="B6" value="57.0" lower_limit="40" upper_limit="64"/>
                    <measurement group_id="B7" value="58.0" lower_limit="50" upper_limit="69"/>
                    <measurement group_id="B8" value="58.0" lower_limit="53" upper_limit="66"/>
                    <measurement group_id="B9" value="59.0" lower_limit="45" upper_limit="69"/>
                    <measurement group_id="B10" value="58.0" lower_limit="37" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With All-causality and Treatment-related Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Treatment-related adverse event (AE) was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.</description>
        <time_frame>From baseline to up to 35 days after last dose for a total of approximately 63 days</time_frame>
        <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to PF-06882961 was administered orally QD or BID(dependent upon corresponding study treatment regimen) for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 10mg BID</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 15mg BID</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 50mg BID</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 70mg BID</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 120mg BID ST</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06882961 200mg QD CR</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-causality and Treatment-related Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Treatment-related adverse event (AE) was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.</description>
          <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-causality AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-causality SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality</title>
        <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin).</description>
        <time_frame>From baseline to up to 14 days after last dose for a total of approximately 42 days</time_frame>
        <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to PF-06882961 was administered orally QD or BID(dependent upon corresponding study treatment regimen) for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 10mg BID</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 15mg BID</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 50mg BID</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 70mg BID</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 120mg BID ST</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06882961 200mg QD CR</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality</title>
          <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin).</description>
          <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Vital Signs</title>
        <description>Vital signs categorical summarization criteria: 1) supine systolic blood pressure (SBP) &lt;90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) &lt;50 mmHg; 3) supine pulse rate &lt;40 or &gt;120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (&gt;=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP &gt;= 20 mmHg.</description>
        <time_frame>From baseline to up to 14 days after last dose for a total of approximately 42 days</time_frame>
        <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to PF-06882961 was administered orally QD or BID(dependent upon corresponding study treatment regimen) for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 10mg BID</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 15mg BID</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 50mg BID</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 70mg BID</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 120mg BID ST</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06882961 200mg QD CR</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Vital Signs</title>
          <description>Vital signs categorical summarization criteria: 1) supine systolic blood pressure (SBP) &lt;90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) &lt;50 mmHg; 3) supine pulse rate &lt;40 or &gt;120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (&gt;=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP &gt;= 20 mmHg.</description>
          <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP &lt;90 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP increase &gt;=30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP decrease &gt;=30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP increase &gt;=20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP decrease &gt;=20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Interval</title>
        <description>ECG categorical summarization criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (&gt;=) 300 millisecond (msec), b) &gt;=25% increase when baseline is &gt; 200 msec or &gt;=50% increase when baseline is less than or equal to (&lt;=) 200 msec.
2. QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) &gt;=140 msec, b) &gt;=50% increase from baseline.
3. QTcF interval (QT corrected using the Fridericia formula): a) &gt;450 msec and &lt;=480 msec, b) &gt;480 msec and &lt;=500 msec, c) &gt;500 msec, d) &gt;30 msec and &lt;=60 msec increase from baseline, e) &gt;60 msec increase from baseline</description>
        <time_frame>From baseline to up to 14 days after last dose for a total of approximately 42 days</time_frame>
        <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to PF-06882961 was administered orally QD or BID(dependent upon corresponding study treatment regimen) for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 10mg BID</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 15mg BID</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 50mg BID</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 70mg BID</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 120mg BID ST</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O9">
            <title>PF-06882961 200mg QD CR</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Interval</title>
          <description>ECG categorical summarization criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (&gt;=) 300 millisecond (msec), b) &gt;=25% increase when baseline is &gt; 200 msec or &gt;=50% increase when baseline is less than or equal to (&lt;=) 200 msec.
2. QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) &gt;=140 msec, b) &gt;=50% increase from baseline.
3. QTcF interval (QT corrected using the Fridericia formula): a) &gt;450 msec and &lt;=480 msec, b) &gt;480 msec and &lt;=500 msec, c) &gt;500 msec, d) &gt;30 msec and &lt;=60 msec increase from baseline, e) &gt;60 msec increase from baseline</description>
          <population>All randomized participants who received at least 1 dose of randomized study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval ≥300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%Change in PR interval ≥25/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration ≥140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%Change in QRS duration ≥50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;450 and ≤480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;480 and ≤500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QTcF interval &gt;30 and ≤60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in QTcF interval &gt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC24 and AUCtau of PF-06882961 on Day 1, Day 14 or 21 and Day 28</title>
        <description>Area under the concentration-time profile from time zero to time 24 hours (AUC24) was calculated as AUCtau1 +AUCtau2, where AUCtau was area under the plasma concentration-time profile from time zero to time tau (tau1 = 0 to 10 hours and tau2=10 to 24 hours). AUCtau was determined using linear/log trapezoidal method.</description>
        <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 1, 14 or 21, and 28</time_frame>
        <population>All randomized participants who received at least 1 dose of PF-06882961 and who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06882961 15mg BID (Cohort 1)</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 50mg BID (Cohort 2)</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 70mg BID (Cohort 3)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 120mg BID (Cohort 4)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 10mg BID (Cohort 5)</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID ST (Cohort 6)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 200mg QD CR (Cohort 7)</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD (Cohort 8)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC24 and AUCtau of PF-06882961 on Day 1, Day 14 or 21 and Day 28</title>
          <description>Area under the concentration-time profile from time zero to time 24 hours (AUC24) was calculated as AUCtau1 +AUCtau2, where AUCtau was area under the plasma concentration-time profile from time zero to time tau (tau1 = 0 to 10 hours and tau2=10 to 24 hours). AUCtau was determined using linear/log trapezoidal method.</description>
          <population>All randomized participants who received at least 1 dose of PF-06882961 and who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram.hours/milliliter (ng.h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC24 on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="707.5" spread="43"/>
                    <measurement group_id="O2" value="1502" spread="29"/>
                    <measurement group_id="O3" value="645.8" spread="52"/>
                    <measurement group_id="O4" value="666.1" spread="54"/>
                    <measurement group_id="O5" value="178.7" spread="72"/>
                    <measurement group_id="O6" value="324.0" spread="41"/>
                    <measurement group_id="O7" value="393.9" spread="80"/>
                    <measurement group_id="O8" value="184.6" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCtau1 on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.1" spread="37"/>
                    <measurement group_id="O2" value="741.4" spread="35"/>
                    <measurement group_id="O3" value="279.7" spread="49"/>
                    <measurement group_id="O4" value="260.3" spread="45"/>
                    <measurement group_id="O5" value="74.50" spread="66"/>
                    <measurement group_id="O6" value="147.7" spread="43"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCtau2 on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.8" spread="50"/>
                    <measurement group_id="O2" value="678.5" spread="79"/>
                    <measurement group_id="O3" value="364.9" spread="56"/>
                    <measurement group_id="O4" value="401.9" spread="62"/>
                    <measurement group_id="O5" value="103.7" spread="76"/>
                    <measurement group_id="O6" value="176.4" spread="42"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC24 on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="853.8" spread="45"/>
                    <measurement group_id="O2" value="2092" spread="91"/>
                    <measurement group_id="O3" value="2988" spread="59"/>
                    <measurement group_id="O4" value="8149" spread="84"/>
                    <measurement group_id="O5" value="201.6" spread="63"/>
                    <measurement group_id="O6" value="2660" spread="76"/>
                    <measurement group_id="O7" value="1291" spread="68"/>
                    <measurement group_id="O8" value="1204" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCtau1 on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348.6" spread="48"/>
                    <measurement group_id="O2" value="880.3" spread="78"/>
                    <measurement group_id="O3" value="1462" spread="70"/>
                    <measurement group_id="O4" value="3772" spread="85"/>
                    <measurement group_id="O5" value="85.57" spread="59"/>
                    <measurement group_id="O6" value="957.3" spread="66"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCtau2 on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500.1" spread="46"/>
                    <measurement group_id="O2" value="1175" spread="110"/>
                    <measurement group_id="O3" value="1517" spread="53"/>
                    <measurement group_id="O4" value="4361" spread="89"/>
                    <measurement group_id="O5" value="115.4" spread="68"/>
                    <measurement group_id="O6" value="1693" spread="83"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC24 on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876.7" spread="41"/>
                    <measurement group_id="O2" value="1653" spread="55"/>
                    <measurement group_id="O3" value="3171" spread="56"/>
                    <measurement group_id="O4" value="8368" spread="79"/>
                    <measurement group_id="O5" value="455.9" spread="66"/>
                    <measurement group_id="O6" value="5973" spread="87"/>
                    <measurement group_id="O7" value="4372" spread="31"/>
                    <measurement group_id="O8" value="2723" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCtau1 on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.1" spread="40"/>
                    <measurement group_id="O2" value="671.1" spread="35"/>
                    <measurement group_id="O3" value="1153" spread="44"/>
                    <measurement group_id="O4" value="3534" spread="87"/>
                    <measurement group_id="O5" value="190.8" spread="60"/>
                    <measurement group_id="O6" value="2249" spread="88"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCtau2 on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="534.7" spread="46"/>
                    <measurement group_id="O2" value="960.1" spread="73"/>
                    <measurement group_id="O3" value="1970" spread="68"/>
                    <measurement group_id="O4" value="4852" spread="74"/>
                    <measurement group_id="O5" value="261.0" spread="72"/>
                    <measurement group_id="O6" value="3668" spread="91"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as AUC24 only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of PF-06882961 on Day 1, Day 14 or 21 and Day 28</title>
        <description>For BID dosing, parameters were calculated for both dosing intervals (0-10 hr = interval 1 and 10-24 hr = interval 2) and were displayed as Cmax1, Cmax2.
Cmax1: maximum plasma concentration during the dosing interval τ1 =0 to 10 hours.
Cmax2: maximum plasma concentration during the dosing interval τ2=10 to 24 hours.</description>
        <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1, 14 or 21, and 28</time_frame>
        <population>All randomized participants treated who had at least 1 measurable concentration value.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06882961 15mg BID (Cohort 1)</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 50mg BID (Cohort 2)</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 70mg BID (Cohort 3)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 120mg BID (Cohort 4)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 10mg BID (Cohort 5)</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID ST (Cohort 6)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 200mg QD CR (Cohort 7)</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD (Cohort 8)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of PF-06882961 on Day 1, Day 14 or 21 and Day 28</title>
          <description>For BID dosing, parameters were calculated for both dosing intervals (0-10 hr = interval 1 and 10-24 hr = interval 2) and were displayed as Cmax1, Cmax2.
Cmax1: maximum plasma concentration during the dosing interval τ1 =0 to 10 hours.
Cmax2: maximum plasma concentration during the dosing interval τ2=10 to 24 hours.</description>
          <population>All randomized participants treated who had at least 1 measurable concentration value.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.58" spread="40"/>
                    <measurement group_id="O2" value="124.4" spread="51"/>
                    <measurement group_id="O3" value="49.75" spread="50"/>
                    <measurement group_id="O4" value="51.61" spread="50"/>
                    <measurement group_id="O5" value="15.02" spread="70"/>
                    <measurement group_id="O6" value="26.02" spread="39"/>
                    <measurement group_id="O7" value="28.67" spread="87"/>
                    <measurement group_id="O8" value="20.40" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax1 on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.69" spread="29"/>
                    <measurement group_id="O2" value="119.1" spread="56"/>
                    <measurement group_id="O3" value="45.01" spread="48"/>
                    <measurement group_id="O4" value="36.51" spread="43"/>
                    <measurement group_id="O5" value="12.82" spread="58"/>
                    <measurement group_id="O6" value="24.06" spread="42"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax2 on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.63" spread="66"/>
                    <measurement group_id="O2" value="68.77" spread="51"/>
                    <measurement group_id="O3" value="42.33" spread="59"/>
                    <measurement group_id="O4" value="44.97" spread="61"/>
                    <measurement group_id="O5" value="13.98" spread="75"/>
                    <measurement group_id="O6" value="21.64" spread="41"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.78" spread="35"/>
                    <measurement group_id="O2" value="149.8" spread="88"/>
                    <measurement group_id="O3" value="253.6" spread="76"/>
                    <measurement group_id="O4" value="788.4" spread="89"/>
                    <measurement group_id="O5" value="18.63" spread="47"/>
                    <measurement group_id="O6" value="188.5" spread="57"/>
                    <measurement group_id="O7" value="98.11" spread="54"/>
                    <measurement group_id="O8" value="100.7" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax1 on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.00" spread="43"/>
                    <measurement group_id="O2" value="130.2" spread="85"/>
                    <measurement group_id="O3" value="235.1" spread="84"/>
                    <measurement group_id="O4" value="682.7" spread="92"/>
                    <measurement group_id="O5" value="15.31" spread="50"/>
                    <measurement group_id="O6" value="143.0" spread="71"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax2 on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.89" spread="36"/>
                    <measurement group_id="O2" value="127.9" spread="86"/>
                    <measurement group_id="O3" value="202.8" spread="50"/>
                    <measurement group_id="O4" value="505.3" spread="93"/>
                    <measurement group_id="O5" value="17.16" spread="58"/>
                    <measurement group_id="O6" value="178.4" spread="56"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.56" spread="32"/>
                    <measurement group_id="O2" value="133.7" spread="69"/>
                    <measurement group_id="O3" value="328.8" spread="49"/>
                    <measurement group_id="O4" value="685.2" spread="87"/>
                    <measurement group_id="O5" value="38.38" spread="58"/>
                    <measurement group_id="O6" value="437.6" spread="94"/>
                    <measurement group_id="O7" value="303.9" spread="32"/>
                    <measurement group_id="O8" value="192.2" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax1 on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.24" spread="44"/>
                    <measurement group_id="O2" value="103.8" spread="50"/>
                    <measurement group_id="O3" value="197.9" spread="51"/>
                    <measurement group_id="O4" value="649.2" spread="90"/>
                    <measurement group_id="O5" value="30.42" spread="52"/>
                    <measurement group_id="O6" value="357.1" spread="84"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax2 on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.22" spread="37"/>
                    <measurement group_id="O2" value="117.2" spread="63"/>
                    <measurement group_id="O3" value="306.5" spread="49"/>
                    <measurement group_id="O4" value="617.9" spread="93"/>
                    <measurement group_id="O5" value="35.01" spread="56"/>
                    <measurement group_id="O6" value="410.3" spread="90"/>
                    <measurement group_id="O7" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">Data was calculated as Cmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Cmax (Tmax) of PF-06882961 on Day 1, Day 14 or 21 and Day 28</title>
        <description>Time for Cmax, Cmax1 and Cmax2 (Tmax, Tmax1 and Tmax2) of PF-06293620 was observed directly from data as time of first occurrence.</description>
        <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 1, 14 or 21, and 28</time_frame>
        <population>All participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06882961 15mg BID (Cohort 1)</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 50mg BID (Cohort 2)</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 70mg BID (Cohort 3)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 120mg BID (Cohort 4)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 10mg BID (Cohort 5)</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID ST (Cohort 6)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 200mg QD CR (Cohort 7)</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD (Cohort 8)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Cmax (Tmax) of PF-06882961 on Day 1, Day 14 or 21 and Day 28</title>
          <description>Time for Cmax, Cmax1 and Cmax2 (Tmax, Tmax1 and Tmax2) of PF-06293620 was observed directly from data as time of first occurrence.</description>
          <population>All participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O7" value="13.0" lower_limit="8.00" upper_limit="23.9"/>
                    <measurement group_id="O8" value="3.00" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax1 on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O6" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax2 on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="10.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="14.0" lower_limit="10.0" upper_limit="24.0"/>
                    <measurement group_id="O3" value="14.0" lower_limit="12.0" upper_limit="14.0"/>
                    <measurement group_id="O4" value="14.0" lower_limit="12.0" upper_limit="24.0"/>
                    <measurement group_id="O5" value="12.0" lower_limit="12.0" upper_limit="14.0"/>
                    <measurement group_id="O6" value="14.0" lower_limit="12.0" upper_limit="24.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O7" value="12.0" lower_limit="6.00" upper_limit="14.0"/>
                    <measurement group_id="O8" value="6.00" lower_limit="4.00" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax1 on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="1.05" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="1.54" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="6.00" lower_limit="4.00" upper_limit="10.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax2 on Day 14 or 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="12.0" upper_limit="14.0"/>
                    <measurement group_id="O2" value="13.0" lower_limit="10.0" upper_limit="14.0"/>
                    <measurement group_id="O3" value="12.0" lower_limit="12.0" upper_limit="12.0"/>
                    <measurement group_id="O4" value="12.0" lower_limit="10.0" upper_limit="14.0"/>
                    <measurement group_id="O5" value="12.0" lower_limit="12.0" upper_limit="14.0"/>
                    <measurement group_id="O6" value="14.0" lower_limit="12.0" upper_limit="24.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax1 and Tmax2 only for BID dosing.</measurement>
                    <measurement group_id="O7" value="14.0" lower_limit="8.00" upper_limit="14.0"/>
                    <measurement group_id="O8" value="10.0" lower_limit="6.00" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax1 on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="6.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="4.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O6" value="6.00" lower_limit="4.00" upper_limit="10.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax2 on Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="12.0" upper_limit="14.0"/>
                    <measurement group_id="O2" value="12.0" lower_limit="12.0" upper_limit="12.0"/>
                    <measurement group_id="O3" value="12.0" lower_limit="12.0" upper_limit="14.0"/>
                    <measurement group_id="O4" value="12.0" lower_limit="12.0" upper_limit="14.0"/>
                    <measurement group_id="O5" value="12.0" lower_limit="12.0" upper_limit="14.0"/>
                    <measurement group_id="O6" value="12.0" lower_limit="10.0" upper_limit="14.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Data was calculated as Tmax only for QD dosing.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t½) of PF-06882961 on Day 28</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 28</time_frame>
        <population>All participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06882961 15mg BID (Cohort 1)</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 50mg BID (Cohort 2)</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 70mg BID (Cohort 3)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 120mg BID (Cohort 4)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 10mg BID (Cohort 5)</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID ST (Cohort 6)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 200mg QD CR (Cohort 7)</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD (Cohort 8)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t½) of PF-06882961 on Day 28</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>All participants randomized and treated who had at least 1 of the PK parameters of interest.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.100" spread="1.2186"/>
                    <measurement group_id="O2" value="5.067" spread="0.75593"/>
                    <measurement group_id="O3" value="4.681" spread="0.59504"/>
                    <measurement group_id="O4" value="6.203" spread="2.3505"/>
                    <measurement group_id="O5" value="8.090" spread="3.3234"/>
                    <measurement group_id="O6" value="6.730" spread="2.5056"/>
                    <measurement group_id="O7" value="5.773" spread="1.4876"/>
                    <measurement group_id="O8" value="4.954" spread="0.58819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Unchanged Drug Recovered in Urine Over 24 Hours (Ae24) of PF-06882961 on Day 28</title>
        <description>Ae was the cumulative amount of drug recovered unchanged in urine during the dosing interval, where the dosing interval was 24 hours. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram [g]/1.020), where 1.020 g/mL was the approximate specific gravity of urine.</description>
        <time_frame>0 to 24 hours post-dose on Day 28</time_frame>
        <population>All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06882961 15mg BID (Cohort 1)</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 50mg BID (Cohort 2)</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 70mg BID (Cohort 3)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 120mg BID (Cohort 4)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 10mg BID (Cohort 5)</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID ST (Cohort 6)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 200mg QD CR (Cohort 7)</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD (Cohort 8)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Unchanged Drug Recovered in Urine Over 24 Hours (Ae24) of PF-06882961 on Day 28</title>
          <description>Ae was the cumulative amount of drug recovered unchanged in urine during the dosing interval, where the dosing interval was 24 hours. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram [g]/1.020), where 1.020 g/mL was the approximate specific gravity of urine.</description>
          <population>All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.</population>
          <units>microgram</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.25" spread="36"/>
                    <measurement group_id="O2" value="33.60" spread="69"/>
                    <measurement group_id="O3" value="41.16" spread="243"/>
                    <measurement group_id="O4" value="NA" spread="NA">&quot;NA&quot; indicates not calculable. There were insufficient number of participants with reportable parameter values (less than 3), so these summary statistics were not calculated.</measurement>
                    <measurement group_id="O5" value="14.97" spread="67"/>
                    <measurement group_id="O6" value="62.63" spread="439"/>
                    <measurement group_id="O7" value="72.98" spread="38"/>
                    <measurement group_id="O8" value="49.09" spread="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae24 (%) of PF-06882961 on Day 28</title>
        <description>Percent of dose recovered in urine as unchanged drug. Ae24% = 100* Ae24/Dose</description>
        <time_frame>0 to 24 hours post-dose on Day 28</time_frame>
        <population>All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06882961 15mg BID (Cohort 1)</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 50mg BID (Cohort 2)</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 70mg BID (Cohort 3)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 120mg BID (Cohort 4)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 10mg BID (Cohort 5)</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID ST (Cohort 6)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 200mg QD CR (Cohort 7)</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD (Cohort 8)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae24 (%) of PF-06882961 on Day 28</title>
          <description>Percent of dose recovered in urine as unchanged drug. Ae24% = 100* Ae24/Dose</description>
          <population>All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.</population>
          <units>Percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05747" spread="36"/>
                    <measurement group_id="O2" value="0.03360" spread="69"/>
                    <measurement group_id="O3" value="0.02942" spread="242"/>
                    <measurement group_id="O4" value="NA" spread="NA">&quot;NA&quot; indicates not calculable. There were insufficient number of participants with reportable parameter values (less than 3), so these summary statistics were not calculated.</measurement>
                    <measurement group_id="O5" value="0.07483" spread="67"/>
                    <measurement group_id="O6" value="0.02607" spread="439"/>
                    <measurement group_id="O7" value="0.03652" spread="38"/>
                    <measurement group_id="O8" value="0.04094" spread="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CLr) of PF-06882961 on Day 28</title>
        <description>CLr was calculated as Ae divided by AUCtau, where dosing interval is 24 hours.</description>
        <time_frame>0 to 24 hours post-dose on Day 28</time_frame>
        <population>All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06882961 15mg BID (Cohort 1)</title>
            <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06882961 50mg BID (Cohort 2)</title>
            <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06882961 70mg BID (Cohort 3)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>PF-06882961 120mg BID (Cohort 4)</title>
            <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>PF-06882961 10mg BID (Cohort 5)</title>
            <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
          </group>
          <group group_id="O6">
            <title>PF-06882961 120mg BID ST (Cohort 6)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
          </group>
          <group group_id="O7">
            <title>PF-06882961 200mg QD CR (Cohort 7)</title>
            <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06882961 120mg QD (Cohort 8)</title>
            <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) of PF-06882961 on Day 28</title>
          <description>CLr was calculated as Ae divided by AUCtau, where dosing interval is 24 hours.</description>
          <population>All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3273" spread="18"/>
                    <measurement group_id="O2" value="0.3385" spread="18"/>
                    <measurement group_id="O3" value="0.3094" spread="70"/>
                    <measurement group_id="O4" value="NA" spread="NA">&quot;NA&quot; indicates not calculable. There were insufficient number of participants with reportable parameter values (less than 3), so these summary statistics were not calculated.</measurement>
                    <measurement group_id="O5" value="0.5470" spread="26"/>
                    <measurement group_id="O6" value="0.2006" spread="228"/>
                    <measurement group_id="O7" value="0.2895" spread="21"/>
                    <measurement group_id="O8" value="0.3178" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 35 days after last dose for a total of approximately 63 days</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and non-serious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matched to PF-06882961 was administered orally QD or BID(dependent upon corresponding study treatment regimen) for a total of 28 days.</description>
        </group>
        <group group_id="E2">
          <title>PF-06882961 10mg BID</title>
          <description>PF-06882961 tablet was administered orally at 5 mg BID from Day 1 to Day 14 followed by a dose of 10 mg BID from Day 15 to Day 28.</description>
        </group>
        <group group_id="E3">
          <title>PF-06882961 15mg BID</title>
          <description>PF-06882961 tablet was administered orally at 15 mg BID for a total of 28 days.</description>
        </group>
        <group group_id="E4">
          <title>PF-06882961 50mg BID</title>
          <description>PF-06882961 tablet was administered orally at 50 mg BID for a total of 28 days.</description>
        </group>
        <group group_id="E5">
          <title>PF-06882961 70mg BID</title>
          <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-3), 40 mg (Day 4-6), 50 mg (Day 7-9) and 70 mg (Day 10-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="E6">
          <title>PF-06882961 120mg BID</title>
          <description>PF-06882961 tablet was administered orally at 20 mg (Day 1-2), 40 mg (Day 3-4), 60 mg (Day 5-6), 80 mg (Day 7-9), 100 mg (Day 10-12) and 120 mg (Day 13-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="E7">
          <title>PF-06882961 120mg BID ST</title>
          <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-4), 20 mg (Day 5-8), 40 mg (Day 9-12), 60 mg (Day 13-16), 80 mg (Day 17-20), 100 mg (Day 21-24) and 120 mg (Day 25-28) BID for a total of 28 days.</description>
        </group>
        <group group_id="E8">
          <title>PF-06882961 120mg QD</title>
          <description>PF-06882961 tablet was administered orally at 10 mg (Day 1-2), 20 mg (Day 3-4), 30 mg (Day 5-6), 40 mg (Day 7-10), 60 mg (Day 11-14), 80 mg (Day 15-18), 100 mg (Day 19-22) and 120 mg (Day 23-28) QD for a total of 28 days.</description>
        </group>
        <group group_id="E9">
          <title>PF-06882961 200mg QD CR</title>
          <description>PF-06882961 CR tablet was administered orally at 50 mg (Day 1-7), 100 mg (Day 8-14), 150 mg (Day 15-21) and 200 mg (Day 22-28) QD for a total of 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>This event occurred in the follow up period and was assessed as not treatment-related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gingivitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thyroid function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

